April 26, 2022
RFA-CA-24-019 - Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
RFA-CA-24-018 - Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
RFA-CA-24-017 - Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
RFA-CA-24-016 - Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional).
RFA-CA-22-001 - Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
RFA-CA-22-002 - Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
RFA-CA-22-003 - Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
RFA-CA-22-004 - Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
RFA-CA-22-021 - Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)
RFA-CA-22-022 - Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
RFA-CA-22-023 - Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
RFA-CA-22-024 - Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
NOT-CA-22-095 - Pre-Application Webinar for NCI's Technologies and Informatics Tools for Cancer Metabolomics NOSI (NOT-CA-22-083)
National Cancer Institute (NCI)
This Notice of Special Interest (NOSI) is to alert the community that the National Cancer Institute (NCI) is seeking to support development of innovative technologies and informatics tools for metabolomics research by leveraging ongoing programs. Innovative technologies for cancer metabolomics can be supported through the Innovative Molecular Analysis Technologies (IMAT) program and informatics tools for cancer metabolomics can be supported through the Informatics Technology for Cancer Research (ITCR) program.
Background
Metabolomics is the systematic study of chemical reactions occurring in organisms, cells, or tissues that involve small molecule substrates, intermediates, and products of metabolism, called metabolites. These small chemicals play key roles in keeping cells healthy and functioning; thus, improving metabolomics technologies and making them more accessible to researchers could advance cancer research across the basic-translational-clinical cancer research continuum.
NCI administers two unique programs focused on the development of technologies that offer transformative potential for advancing cancer research. The Innovative Molecular Analysis Technologies (IMAT) program supports highly innovative, data-generating platforms and methodologies. The program solicits grant applications for early-stage development of novel tools and methods that enable cancer researchers across the entire spectrum of cancer research. The Informatics Technologies for Cancer Research (ITCR) program supports powerful data analysis, management, and visualization technologies. The program supports research-driven informatics technology development spanning all aspects of cancer research and across the tool development lifecycle.
The NCI seeks to stimulate technology development to facilitate transformational new approaches for cancer metabolomics and lipidomics research through the IMAT and ITCR programs. Therefore, this announcement seeks to address the need for new technologies designed explicitly to overcome technical challenges and advance cancer metabolomics. Such research could include, but is not limited to, launching new and innovative analytical and software platforms, improving the ability of researchers to process more complex samples or increase sample throughput, and/or developing novel computational approaches or tools that facilitate metabolomics data analysis, interpretation, and integration.
Specific Areas of Research Interest
Both IMAT and ITCR support projects across the continuum of basic-translational-clinical cancer research.
Innovative Molecular Analysis Technologies (IMAT)
- IMAT supports both molecular and cellular analysis technologies and biospecimen science technologies. For each of these areas, IMAT uses the R61 mechanism for early-stage exploratory projects where preliminary data is not required and the R33 mechanism for the advanced development stage that requires feasibility data.
- IMAT innovative molecular and cellular technologies are solicited through RFA-CA-22-001 for early-stage R61 projects and through RFA-CA-22-002 for advanced development stage R33 projects.
- IMAT biospecimen science technologies are solicited through RFA-CA-22-003 for early-stage R61 projects and through RFA-CA-22-004 for advanced development stage R33 projects.
- The IMAT program requires the provision of quantitative performance measures to accompany the aims of any proposed research. Applications that fail to include adequate performance measures will not be reviewed.
Informatics Technology for Cancer Research (ITCR)
- ITCR supports research-driven informatics technology development spanning all aspects of cancer research. The four ITCR funding mechanisms are tailored to successive stages of the informaitcs development lifecycle.
- The R21 (RFA-CA-22-021) supports the development of innovative methods and algorithms in biomedical computing, informatics, and data science.
- The U01 (RFA-CA-22-022) supports prototyping and hardening of informatics technologies.
- There are two U24 funding opportunities for later stage development. RFA-CA-22-023 supports enhancement and dissemination of emerging technologies while RFA-CA-22-024 supports the sustainment of highly accessed tools.
The following tools and technologies are of particular interest to NCI:
- Tools and technologies that support for lipidomics research
- Tools and technologies for integrating metabolomics with other -omic approaches
- Tools and technologies for use in low-resource settings in low- and middle-income countries (LMICs)
Proposals to this NOSI should consider the following:
- Projects in response to this Notice of Special Interest must address topics within the scientific scope of the relevant RFA
- Each RFA has specific requirements and non-responsive criteria that must be considered, and applicants are strongly encouraged to read all instructions in the relevant RFAs and to reach out to the relevant staff contact with any questions
Application and Submission Information
This notice applies to due dates on or after June 14, 2022, and subsequent receipt dates through December 31, 2024.
Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these FOAs through the expiration date of this notice.
|
Technology Area |
Technology Stage |
Mechanism |
RFA |
Budget |
First Available Due Date |
|
Molecular and cellular analysis technologies |
Early-stage exploratory projects |
Direct costs are limited to $150,000 per year for up to 3 years. |
September 22, 2022 |
||
|
Molecular and cellular analysis technologies |
Developmental-stage projects |
Direct costs are limited to $300,000 per year for up to 3 years. |
September 22, 2022 |
||
|
Biospecimen science technologies |
Early-stage exploratory projects |
Direct costs are limited to $150,000 per year for up to 3 years. |
September 22, 2022 |
||
|
Biospecimen science technologies |
Developmental-stage projects |
Direct costs are limited to $300,000 per year for up to 3 years. |
September 22, 2022 |
||
|
Informatics tools |
Algorithm development |
Direct costs are limited to $275,000 over a two-year period. No more than $200,000 may be requested in any single year. |
June 14, 2022 |
||
|
Informatics tools |
Prototyping and hardening |
Direct Costs are limited to $300,000 (excluding consortium F&A) per year. |
June 14, 2022 |
||
|
Informatics tools |
Enhancement and dissemination |
Direct Costs are limited to $600,000 (excluding consortium F&A) per year. |
June 14, 2022 |
||
|
Informatics tools |
Sustainment |
Application budgets are not limited but need to reflect the actual needs of the proposed project. |
June 14, 2022 |
All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:
- For funding consideration, applicants must include NOT-CA-22-083 (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.
Scientific/Research Contact(s)
Sean Hanlon, PhD
National Cancer Institute (NCI)
Telephone: 240-281-3310
Email: [email protected]
Peer Review Contact(s)
Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).
Financial/Grants Management Contact(s)
Crystal Wolfrey
National Cancer Institute
Telephone: 240-276-6277
Email: [email protected]
and Human Services (HHS)
